^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    solnerstotug (SNS-101)

    i
    Other names: SNS-101, SNS-VISTA, V-set immunoglobulin domain suppressor of T cell activation
    Associations

    News

    Trials
    Company:
    Sensei Biotherap
    Drug class:
    VISTA antagonist
    Related drugs:
    Associations

    News

    Trials
    4ms
    SNS-101-2-1: A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=98, Active, not recruiting, Sensei Biotherapeutics, Inc. | Recruiting --> Active, not recruiting | N=169 --> 98
    Enrollment closed • Enrollment change
    |
    Libtayo (cemiplimab-rwlc) • solnerstotug (SNS-101)
    over1year
    VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. (PubMed, Nat Commun)
    In syngeneic tumor models utilizing human VISTA knock-in mice, SNS-101 shows in vivo efficacy when combined with a PD-1 inhibitor, modulates cytokine and chemokine signaling, and alters the tumor microenvironment. In summary, SNS-101, currently in Phase I clinical trials, emerges as a promising therapeutic biologic for a wide range of patients whose cancer is refractory to current immunotherapy regimens.
    PK/PD data • Journal • Checkpoint inhibition
    |
    PD-1 (Programmed cell death 1)
    |
    solnerstotug (SNS-101)
    almost2years
    A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=169, Recruiting, Sensei Biotherapeutics, Inc. | N=129 --> 169
    Enrollment change • Combination therapy • Metastases
    |
    Libtayo (cemiplimab-rwlc) • solnerstotug (SNS-101)
    over2years
    A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=129, Recruiting, Sensei Biotherapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Libtayo (cemiplimab-rwlc) • solnerstotug (SNS-101)
    over2years
    A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=129, Not yet recruiting, Sensei Biotherapeutics, Inc.
    New P1/2 trial • Combination therapy • Metastases
    |
    Libtayo (cemiplimab-rwlc) • solnerstotug (SNS-101)